0IV3 Stock Overview
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Geron Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.58 |
| 52 Week High | US$4.01 |
| 52 Week Low | US$1.73 |
| Beta | 0.61 |
| 1 Month Change | 8.66% |
| 3 Month Change | 66.28% |
| 1 Year Change | 47.73% |
| 3 Year Change | 138.02% |
| 5 Year Change | 97.52% |
| Change since IPO | 76.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0IV3 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -5.2% | 0.5% | 2.7% |
| 1Y | 47.7% | -29.8% | 0.3% |
Return vs Industry: 0IV3 exceeded the UK Biotechs industry which returned -29.8% over the past year.
Return vs Market: 0IV3 exceeded the UK Market which returned 0.3% over the past year.
Price Volatility
| 0IV3 volatility | |
|---|---|
| 0IV3 Average Weekly Movement | 28.1% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0IV3's share price has been volatile over the past 3 months.
Volatility Over Time: 0IV3's weekly volatility has increased from 16% to 28% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 141 | Chip Scarlett | www.geron.com |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation Fundamentals Summary
| 0IV3 fundamental statistics | |
|---|---|
| Market cap | US$2.06b |
| Earnings (TTM) | -US$184.13m |
| Revenue (TTM) | US$237.00k |
8,895x
P/S Ratio-11.4x
P/E RatioIs 0IV3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0IV3 income statement (TTM) | |
|---|---|
| Revenue | US$237.00k |
| Cost of Revenue | US$123.74m |
| Gross Profit | -US$123.50m |
| Other Expenses | US$60.62m |
| Earnings | -US$184.13m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | -52,110.97% |
| Net Profit Margin | -77,690.72% |
| Debt/Equity Ratio | 33.0% |
How did 0IV3 perform over the long term?
See historical performance and comparison